0000899243-17-002061.txt : 20170126 0000899243-17-002061.hdr.sgml : 20170126 20170126200241 ACCESSION NUMBER: 0000899243-17-002061 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170126 FILED AS OF DATE: 20170126 DATE AS OF CHANGE: 20170126 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1030 MASSACHUSETTS AVE. CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 1030 MASSACHUSETTS AVE. CITY: CAMBRIDGE STATE: MA ZIP: 02138 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hadley Harbor Master Investors (Cayman) L.P. CENTRAL INDEX KEY: 0001641080 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 17551396 BUSINESS ADDRESS: STREET 1: ELIAN FIDUCIARY SERVICES (CAYMAN) LTD STREET 2: 89 NEXUS WAY, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-9007 BUSINESS PHONE: 617-790-7163 MAIL ADDRESS: STREET 1: ELIAN FIDUCIARY SERVICES (CAYMAN) LTD STREET 2: 89 NEXUS WAY, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-9007 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2017-01-26 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001641080 Hadley Harbor Master Investors (Cayman) L.P. C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 0 0 1 0 No securities are benefically owned 0 D Series B Convertible Preferred Stock Common Stock 719476 D Each share of Series B convertible preferred stock is convertible into 0.271003 shares of common stock at the option of the reporting person or upon the occurrence of certain events. All outstanding shares of Series B convertible preferred stock are expected to convert into shares of common stock immediately prior to the amendment and restatement by Jounce Therapeutics, Inc. of its certificate of incorporation, provided the amendment and restatement occurs prior to, and on the same day as, the closing of its initial public offering at an initial public offering price that results in at least $35 million of gross proceeds, after deducting the underwriting discount and commissions, to Jounce Therapeutics, Inc. Hadley Harbor Master Investors (Cayman) L.P., By: Wellington Alternative Investments LLC, as General Partner, /s/ Matthew N. Shea, Title: Managing Director and Counsel 2017-01-24